Kodiak Sciences' Pipeline Shows Promise Amid Financing Challenges
Kodiak Sciences details retinal drug pipeline
Kodiak Sciences’ 10-K highlights Zenkuda Phase 3 successes, an expanding KSI-501 and KSI-101 pipeline, Lonza-backed manufacturing, and a disclosed going-concern risk tied to future financing and pivotal readouts from 3Q 2026 onward.
Kodiak Sciences released its 10-K filing detailing strong Phase 3 progress for Zenkuda and expansion of its KSI-501 and KSI-101 pipeline programs for retinal diseases. The biotech company, backed by manufacturing partner Lonza, disclosed going-concern risks dependent on future financing and critical pivotal trial readouts expected in Q3 2026 and beyond.
Original Article
Read full article on sourceExplore More
Related News
Health Sciences Weekend Unites Alumni Around Shared Health Science Center Story - UTHSC News
UTHSC News · 2026.04.14
Molecular Sciences Building - Premier Construction
ROMA Publications Ltd · 2026.04.14
Designing Winners - College of Arts and Sciences
College of Arts and Sciences · 2026.04.14
8 Best Life Sciences Penny Stocks to Buy
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey · 2026.04.14
MAHA and science-based public health: Can’t we all just get along? | Science-Based Medicine
Science-Based Medicine · 2026.04.15
Monmouth College Enhances Computer Science Program
River Cities’ Reader · 2026.04.14